Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Recent patents report novel analgesic agents

Sep. 29, 2006

R&D highlights from the UBS Global Life Sciences Conference in New York: NeurogesX

Sep. 29, 2006

ACV-1 enters phase II for neuropathic pain

Sep. 29, 2006

Elan and Transition Therapeutics collaborate on AZD-103 for Alzheimer's

Sep. 29, 2006

Novel antioxidant compounds show benefit in a mouse model of amyotrophic lateral sclerosis

Sep. 28, 2006

Fampridine-SR meets all SPA efficacy criteria in MS walking study

Sep. 28, 2006

CytRx reports encouraging results from phase IIa ALS trial with arimoclomol

Sep. 28, 2006

Pagoclone advances for stuttering, discontinued for premature ejaculation

Sep. 28, 2006

Phase II results with FTY-720 in multiple sclerosis encourage phase III program

Sep. 28, 2006

Presentations outline agomelatine efficacy in treating depression

Sep. 28, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...